

ONCOLYTICS BIOTECH INC  
Form 8-A12B  
May 31, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR 12(g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

**Oncolytics Biotech Inc.**

(Exact name of registrant as specified in its charter)

**Alberta, Canada**

(State of incorporation or organization)

**Not Applicable**

(I.R.S. Employer Identification No.)

**Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, Canada T2N 1X7**

(Address of principal executive offices)

(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class  
to be so registered

Name of each exchange on which  
each class is to be registered

**Common Shares, no par value The Nasdaq Stock Market LLC**

Edgar Filing: ONCOLYTICS BIOTECH INC - Form 8-A12B

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.

Securities Act registration statement file number to which this form relates: (if applicable)

Securities to be registered pursuant to Section 12(g) of the Act: **None**

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant's Securities to be Registered.

The description of the common shares, without par value, of Oncolytics Biotech Inc. (the "**Registrant**") contained in the Registrant's Registration Statement on Form F-10 under the heading "Description of Share Capital", originally filed on April 25, 2018, as amended on May 4, 2018, with the United States Securities and Exchange Commission (File No. 333-224432), is incorporated herein by this reference in response to this item.

Item 2. Exhibits.

**ITEM 2. EXHIBITS.**

Exhibit

	<u>Description of Exhibits</u>
<u>Number</u>	
3.1	Articles of Incorporation
3.2	Bylaws
4.1	Form of Warrant Indenture, dated June 1, 2017, by and between the Company and Computershare Trust Company of Canada
4.2	Form of Warrant between the Company and Adlai Norte Biopharma Inc.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)Oncolytics Biotech Inc.

Date May 31, 2018

By /s/ Kirk Look  
Kirk Look  
Chief Financial Officer

2